Is It Time To Revisit Vertex Pharmaceuticals (VRTX) After The Recent Share Price Pullback?
- If you are wondering whether Vertex Pharmaceuticals at around US$436 a share is offering value or asking you to pay up for quality, this article will help you frame that question clearly.
- The stock is currently around 7% lower over the past month and about 9.9% lower over the last year, even though the 3 year and 5 year returns of 30.8% and 98.9% present a very different picture.
- Recent attention on Vertex has centered on its position in high value therapies and the broader discussion about how markets are pricing established biotech names versus younger peers. That mix of long term interest and near term hesitation is an important backdrop for thinking about what the current share price really reflects.
- Right now, Vertex carries a valuation score of 4 out of 6. The rest of this article will walk through what different valuation approaches say about that number and point you toward an even more complete way to assess value at the end.
Find out why Vertex Pharmaceuticals's -9.9% return over the last year is lagging behind its peers.
Approach 1: Vertex Pharmaceuticals Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model takes estimates of a company’s future cash flows and discounts them back to today to arrive at an estimate of what the business might be worth per share.
For Vertex Pharmaceuticals, the latest twelve month free cash flow is about $3.18b. Using a 2 Stage Free Cash Flow to Equity model, analysts provide detailed projections out to 2030, with free cash flow for that year estimated at $7.57b. Beyond the first few years of analyst coverage, Simply Wall St extrapolates the later cash flows to complete a 10 year path.
When those projected cash flows are discounted back to today and divided by the share count, the DCF model arrives at an estimated intrinsic value of about $753.74 per share. Against a current share price around $436, the model implies the stock trades at roughly a 42.1% discount to this estimate. This suggests an undervalued reading based on these cash flow assumptions.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Vertex Pharmaceuticals is undervalued by 42.1%. Track this in your watchlist or portfolio, or discover 58 more high quality undervalued stocks.
Approach 2: Vertex Pharmaceuticals Price vs Earnings
For profitable companies, the P/E ratio is a straightforward way to relate what you pay for a share to the earnings that each share currently generates. It helps you judge whether the market is putting a higher or lower price on each dollar of profit.
What counts as a "normal" or "fair" P/E depends on how the market views a company’s growth prospects and risk profile. Higher growth and lower perceived risk can support higher P/E multiples, while slower growth or higher perceived risk usually point to lower P/E levels.
Vertex currently trades on a P/E of 28.07x. That sits above the broader Biotechs industry average of 17.55x, but below the peer group average of 37.44x. Simply Wall St also calculates a proprietary "Fair Ratio" of 27.44x for Vertex, which reflects factors like its earnings growth profile, industry, profit margins, market cap and company specific risks.
This Fair Ratio is more tailored than a simple comparison with peers or the industry because it adjusts for those company specific characteristics rather than assuming all biotechs deserve the same multiple. With the actual P/E at 28.07x versus a Fair Ratio of 27.44x, Vertex screens as slightly expensive on this metric.
Result: OVERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.
Upgrade Your Decision Making: Choose your Vertex Pharmaceuticals Narrative
Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as simple stories that you attach to the numbers, where you spell out what you think Vertex Pharmaceuticals' future revenue, earnings and margins could look like, and connect that view to a Fair Value estimate that can be compared with today’s share price.
On Simply Wall St’s Community page, Narratives give you an accessible way to tie the company’s story to a full financial forecast and Fair Value. This can help you decide whether the current price around US$436 lines up with your view or not. These Narratives refresh automatically as new information such as news, earnings or clinical data is added to the platform used by millions of investors.
For example, one Vertex Narrative assumes a Fair Value of US$641.00 with revenue growing around 15.7% a year, margins rising to about 46.5% and earnings reaching roughly US$8.6b by 2029 at a P/E of 22.4x. A more cautious Narrative uses a Fair Value of about US$403.80 with revenue growth around 3.2%, net margins near 25.0% and a higher future P/E of 36.9x. Comparing these storylines side by side can clarify which version of the future you think the current share price already reflects.
For Vertex Pharmaceuticals however, we will make it really easy for you with previews of two leading Vertex Pharmaceuticals Narratives:
🐂 Vertex Pharmaceuticals Bull Case
Fair value: US$641.00
Implied discount vs last close: around 32% below this fair value
Revenue growth assumption: 15.7% a year
- Sees ALYFTREK, JOURNAVX and the renal portfolio extending Vertex's leadership in chronic and genetic diseases and broadening the revenue base.
- Builds in higher earnings and margin potential, with analysts expecting revenue of US$18.6b and earnings of US$8.6b by 2029 at a future P/E of 22.4x.
- Flags dependence on cystic fibrosis, pricing pressure and rising competition as key risks that could challenge this higher fair value.
🐻 Vertex Pharmaceuticals Bear Case
Fair value: US$403.80
Implied premium vs last close: about 8% above this fair value
Revenue growth assumption: 3.2% a year
- Assumes tighter drug pricing, higher R&D needs and smaller target populations will limit revenue growth and pressure margins over time.
- Builds a slower earnings path, with analysts using revenue of US$12.5b and earnings of US$4.8b by 2028 at a higher future P/E of 36.9x.
- Highlights risk that reliance on cystic fibrosis and competitive gene and cell therapy pipelines could cap upside if new launches underwhelm.
If the numbers and story in one preview feel closer to your own view of Vertex's future, that Narrative can be a useful anchor for your ongoing research rather than treating the current share price as the only reference point.
See what the community is saying about Vertex Pharmaceuticals
Do you think there's more to the story for Vertex Pharmaceuticals? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com